Efficacy, Safety, and Tolerability of Dupilumab in Patients With Persistent Moderate to Severe Eosinophilic Asthma
Completed · Phase 2 · NCT01312961
Conditions: Asthma
At a glance
- Research payments reported, 2025
- $36,250
- U.S. investigators named
- 0
- Sites paid
- 0
- Planned or actual enrollment
- 104
About the trial
- Sponsor
- Sanofi (with Regeneron Pharmaceuticals)
- Tested
- Dupilumab (drug), Placebo (for Dupilumab) (drug), Fluticasone/Salmeterol combination therapy (drug), Fluticasone monotherapy (drug), Albuterol (drug), Levalbuterol (drug)
- Dates
- Started 2011-03; completion 2012-10
- Results posted
- Yes
Primary Objective: To investigate the effects of Dupilumab (SAR231893/REGN668) administered subcutaneously (SC) once weekly (qw) for 12 weeks as compared to placebo on reducing the incidence of asthma exacerbation in participants with persistent moderate to severe eosinophilic asthma. Secondary Objectives: * To assess the safety and tolerability of Dupilumab administered SC qw for 12 weeks in participants with persistent moderate to severe eosinophilic asthma. * To assess Dupilumab serum concentrations following qw SC dosing for 12 weeks in participants with persistent moderate to severe eosinophilic asthma.
From ClinicalTrials.gov, last updated 2017-06-08. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Genzyme Corporation reported $36,250 in research payments for this study in 2025 (99 payments).
Products named: Dupixent
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
Sites paid to run it
- $36,250
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.